Enhancement of 5-fluorouracil's anticancer activity by dipyridamole.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Pharmacology and Therapeutics

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0163-7258(89)90084-3PMID 2646650
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of dipyridamole.

  2009cited by this paper
• Studies on Fluorinated Pyrimidines XI . In Vitro Studies on Tumor Resistance

  2006cited by this paper
• 5-Fluorouracil Mechanisms of Sensitivity and Resistance of Murine Tumors to Updated Version

  2006cited by this paper
• Methotrexate or 5-Fluorouracil Mouse 5178 Y Lymphoma Cells following Exposure to Changes in the Deoxyribonucleoside Triphosphate Pools of Updated Version

  2006cited by this paper
• Pharmacokinetics of oral dipyridamole (Persantine®) and its effect on platelet adenosine uptake in man

  2004cited by this paper
• Kinetic study of the irreversible thermal denaturation of Bacillus licheniformis alpha-amylase.

  1989cited by this paper
• Dipyridamole Decreases Platelet‐Derived Growth Factor Levels in Human Serum

  1987cited by this paper
• Dipyridamole stimulates urokinase production and suppresses procoagulant activity of rabbit alveolar macrophages: a possible mechanism of antithrombotic action.

  1987cited by this paper
• Drug therapy. Dipyrimadole

  1987cited by this paper
• Dipyridamole.

  1987cited by this paper
• Augmentation of methotrexate cytotoxicity in human colon cancer cells achieved through inhibition of thymidine salvage by dipyridamole.

  1987cited by this paper
• A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.

  1987cited by this paper
• Nucleoside Transport Inhibition In Vitro and In Vivo

  1987cited by this paper
• The effect of the nucleoside transport inhibitor dipyridamole on the incorporation of [3H]thymidine in the rat.

  1986cited by this paper
• Inhibition of nucleoside and nucleobase transport and nitrobenzylthioinosine binding by dilazep and hexobendine.

  1986cited by this paper
• Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels.

  1986cited by this paper
• Expression of a novel high-affinity purine nucleobase transport function in mutant mammalian T lymphoblasts

  1986cited by this paper
• Modulation of fluorouracil metabolism and cytotoxicity by nitrothiobenzylinosine.

  1986cited by this paper
• Changes in nucleoside transport of HL-60 human promyelocytic cells during N,N-dimethylformamide induced differentiation.

  1986cited by this paper
• The effect of 3-deazauridine and dipyridamole on uridine utilization by mice.

  1986cited by this paper
• Incomplete nucleoside transport deficiency with increased hypoxanthine transport capability in mutant T-lymphoblastoid cells

  1986cited by this paper
• Alteration of the secondary structure of newly synthesized DNA from murine bone marrow cells by 5-fluorouracil.

  1986cited by this paper
• Photoaffinity labelling of a nitrobenzylthioinosine-binding polypeptide from cultured Novikoff hepatoma cells.

  1986cited by this paper
• Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells.

  1986cited by this paper
• Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.

  1986cited by this paper
• Dipyridamole-insensitive nucleoside transport in mutant murine T lymphoma cells.

  1986cited by this paper
• Clinical implications of tumor-cell heterogeneity.

  1986cited by this paper
• Tissue uridine pools: evidence in vivo of a concentrative mechanism for uridine uptake.

  1986cited by this paper
• Amphotericin B renders stationary phase hepatoma cells sensitive to dipyridamole.

  1986cited by this paper
• Inhibitors of "spontaneous" platelet aggregation in whole blood.

  1985cited by this paper
• Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine.

  1985cited by this paper
• Characterization of mouse lymphoma cells with altered nucleoside transport

  1985cited by this paper
• Pharmacologically directed ara-C therapy for refractory leukemia.

  1985cited by this paper
• Genetic Analysis of the 6-Thiobenzylpurine Binding Site of the Nucleoside Transporter in Mouse Lymphoblasts

  1985cited by this paper
• Resistance of CCRF-CEM cloned sublines to 5-fluorodeoxyuridine associated with enhanced phosphatase activities.

  1985cited by this paper
• Modulation of the activity of PALA by dipyridamole.

  1985cited by this paper
• Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole.

  1985cited by this paper
• Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.

  1985cited by this paper
• Role of Nucleoside Transport in Drug Action The Adenosine Deaminase Inhibitor, Deoxycoformycin, and the Antiplatelet Drugs, Dipyridamole and Dilazep a

  1985cited by this paper
• Nucleoside transport in Walker 256 rat carcinosarcoma and S49 mouse lymphoma cells. Differences in sensitivity to nitrobenzylthioinosine and thiol reagents.

  1985cited by this paper
• Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia.

  1985cited by this paper
• Theophylline antagonizes cardiovascular responses to dipyridamole in man without affecting increases in plasma adenosine.

  1984cited by this paper
• Interaction between 5-fluorouracil and DNA of human colon adenocarcinoma.

  1984cited by this paper
• Incorporation of 5-fluorouracil into murine bone marrow DNA in vivo.

  1984cited by this paper
• Enhancement of the sensitivity of human colon cancer cells to growth inhibition by acivicin achieved through inhibition of nucleic acid precursor salvage by dipyridamole.

  1984cited by this paper
• Modulation of cytarabine uptake and toxicity by dipyridamole.

  1984cited by this paper
• Persantine bioavailability problems.

  1984cited by this paper
• Potentiation of methotrexate toxicity by dipyridamole.

  1984cited by this paper
• Nucleoside transport in cultured mammalian cells. Multiple forms with different sensitivity to inhibition by nitrobenzylthioinosine or hypoxanthine.

  1984cited by this paper
• Specificity and Sodium Dependence of the Active Nucleoside Transport System in Choroid Plexus

  1984cited by this paper
• Tumor heterogeneity.

  1984cited by this paper
• Sodium gradient-energized concentrative transport of adenosine in renal brush border vesicles

  1984cited by this paper
• Drugs Effect on Platelet Survival Time: Comparison of Two Pyrimido-Pyrimidine Derivatives in Patients with Aortic or Mitral Replacement

  1984cited by this paper
• 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity.

  1984cited by this paper
• A Comparison of Spontaneous Platelet Aggregation in Whole Blood with Platelet Rich Plasma: Additional Evidence for the Role of ADP

  1984cited by this paper
• Inhibition of the transport of adenosine, other nucleosides and hypoxanthine in novikoff rat hepatoma cells by methylxanthines, papaverine, N6-cyclohexyladenosine and N6-phenylisopropyladenosine.

  1984cited by this paper
• Enzymic capacities of purine de Novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues.

  1984cited by this paper
• Effects of acivicin and dipyridamole on hepatoma 3924A cells.

  1983cited by this paper
• Nucleoside transport in animal cells

  1983cited by this paper
• The kinetics of dissociation of the inhibitor of nucleoside transport, nitrobenzylthioinosine, from the high-affinity binding sites of cultured hamster cells.

  1983cited by this paper
• Clinical pharmacokinetics of dipyridamole.

  1983cited by this paper
• Fluorinated pyrimidines and their nucleosides.

  1983cited by this paper
• Mechanism of action of dipyridamole.

  1983cited by this paper
• Nitrobenzylthioinosine-insensitive uridine transport in human lymphoblastoid and murine leukemia cells.

  1983cited by this paper
• Human tumor cell heterogeneity and metastasis.

  1983cited by this paper
• Plasma Dipyridamole Concentrations After Two Different Dosage Regimens in Patients

  1983cited by this paper
• Heterogeneity of nucleoside transport in mammalian cells. Two types of transport activity in L1210 and other cultured neoplastic cells.

  1983cited by this paper
• Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture.

  1983cited by this paper
• Salvage capacity of hepatoma 3924A and action of dipyridamole.

  1983cited by this paper
• Antiviral action of dipyridamole and its derivatives against influenza virus A.

  1982cited by this paper
• 5-Fluorouracil incorporation in DNA of human breast carcinoma cells.

  1982cited by this paper
• Thymidylate synthetase levels as a factor in 5-fluorodeoxyuridine and methotrexate cytotoxicity in gastrointestinal tumor cells.

  1982cited by this paper
• Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines.

  1982cited by this paper
• Dipyridamol kinetics.

  1982cited by this paper
• Dipyridamole is an interferon inducer.

  1982cited by this paper
• The Role of Cyclic Nucleotides in Platelets

  1982cited by this paper
• Transport of nucleoside drugs in animal cells.

  1981cited by this paper
• The pharmacology of the fluoropyrimidines.

  1981cited by this paper
• Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate cytotoxicity.

  1981cited by this paper
• An update on the biochemistry of 5-fluorouracil.

  1981cited by this paper
• Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells.

  1980cited by this paper
• DIPYRIDAMOLE: A POTENT STIMULATOR OF PROSTACYCLIN (PGI2) BIOSYNTHESIS

  1980cited by this paper
• Disease-induced Changes in the Plasma Binding of Basic Drugs

  1980cited by this paper
• Mechanisms of sensitivity and resistance of murine tumors to 5-fluorouracil.

  1980cited by this paper
• A common basis for inhibition of nucleoside transport by dipyridamole and nitrobenzylthioinosine?

  1980cited by this paper
• Increased thymidylate synthetase in 5-fluorodeoxyuridine resistant cultured hepatoma cells.

  1980cited by this paper
• Quantitative high-performance liquid chromatography of nucleosides and bases in human plasma.

  1980cited by this paper
• Permeation of Nucleosides, Nucleic Acid Bases, and Nucleotides in Animal Cells

  1980cited by this paper
• Effects of aspirin and dipyridamole on the degradation of adenosine diphosphate by cultured cells derived from bovine pulmonary artery.

  1980cited by this paper
• Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture.

  1979cited by this paper
• Identification and quantitation of nucleosides, bases and other UV-absorbing compounds in serum, using reversed-phase high-performance liquid chromatography. II. Evaluation of human sera.

  1979cited by this paper
• Mode of action of dipyridamole on human platelets.

  1979cited by this paper
• Low specificity of the nucleoside transport mechanism of RPMI 6410 cells.

  1979cited by this paper
• Metabolism of 5-fluorouracil in cultured cells. Protection from 5-fluorouracil cytotoxicity by purines.

  1979cited by this paper
• Fluctuations in nucleoside uptake and binding of the inhibitor of nucleoside transport, nitrobenzylthioinosine, during the replication cycle of HeLa cells.

  1979cited by this paper
• Identification and quantitation of nucleosides, bases and other UV-absorbing compounds in serum, using reversed-phase high-performance liquid chromatography : II. Evaluation of human era

  1979cited by this paper
• Identification and quantitation of nucleosides, bases and other UV-absorbing compounds in serum, using reversed-phase high-performance liquid chromatography. I. Chromatographic methodology.

  1979cited by this paper
• Stimulation of prostacyclin by dipyridamole.

  1979cited by this paper
• Tumor 5-fluorodeoxyuridylate concentration as a determinant of 5-fluorouracil response.

  1978cited by this paper
• Properties of the thymidine transport system of chinese hamster ovary cells as probed by nitrobenzylthioinosine

  1978cited by this paper

• Sodium Butyrate Enhances 5‐Fluorouracil Sensitivity Through Thymidylate Synthase Regulation and Cell‐Cycle Modulation in Gastric Cancer

  2025cites this paper
• 5-Fluorouracil (5-FU)-induced organ toxicities: mechanisms, management, and prevention strategies

  2025cites this paper
• Differential functionality of fluoropyrimidine nucleosides for safe cancer therapy

  2024cites this paper
• Preparation of nanoformulation of 5-fluorouracil to improve anticancer efficacy: integrated spectroscopic, docking, and MD simulation approaches

  2023cites this paper
• Stress Granules in the Anti-Cancer Medications Mechanism of Action: A Systematic Scoping Review

  2021cites this paper
• Star-Shaped Polylactide Dipyridamole Conjugated to 5-Fluorouracil and 4-Piperidinopiperidine Nanocarriers for Bioimaging and Dual Drug Delivery in Cancer Cells

  2021cites this paper
• Fluorouracil or Capecitabine Overdose

  2021cites this paper
• Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation.

  2019cites this paper
• Dipyridamole impairs autophagic flux and exerts antiproliferative activity on prostate cancer cells.

  2019cites this paper
• 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future.

  2019cites this paper
• TNF-α sensitizes chemotherapy and radiotherapy against breast cancer cells

  2017cites this paper
• Long non-coding RNA-based mechanisms for the inhibition of cell growth and development by 5 - Fluorouracil

  2016cites this paper
• In Vitro Anticancer Activity of Ethanolic Extract of Euphorbia hirta (L.)

  2014cites this paper
• Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells.

  2013cites this paper
• Combined 5-FU and ChoKα Inhibitors as a New Alternative Therapy of Colorectal Cancer: Evidence in Human Tumor-Derived Cell Lines and Mouse Xenografts

  2013cites this paper
• AN IN VITRO STUDY OF CYTOTOXIC ACTIVITY OF EUPHORBIA HIRTA ON HEP­2 CELLS OF HUMAN EPITHELIOMA OF LARYNX

  2011cites this paper
• Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare.

  2010cites this paper
• 5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs

  2010cites this paper
• The role of E-cadherin in colon cancer drug resistance

  2010cites this paper
• A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?

  2009cites this paper
• 5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies

  2008cites this paper
• The effects of de novo dTMP inhibition by N-f5-[N-(3,4-dihydro-2- methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl}-L-

  2006cites this paper
• Drifter technique: a new method to obtain metaphases in Hep-2 cell line cultures

  2005cites this paper
• Molecular mechanisms of drug resistance

  2005cites this paper
• Dipyridamole increases the cytotoxicity of cisplatin in human larynx cancer cells in vitro.

  2004cites this paper
• 5-Fluorouracil: mechanisms of action and clinical strategies

  2003cites this paper
• Leucovorin + 5-Fluorouracil plus Dipyridamole in Leucovorin + 5-Fluorouracil-Pretreated Patients with Advanced Colorectal Cancer: A Pilot Study of Three Different Dipyridamole Regimens

  2001cites this paper
• Monitoring of the intracellular activation of 5‐fluorouracil to deoxyribonucleotides in HT29 human colon cell line: application to modulation of metabolism and cytotoxicity study

  2000cites this paper
• Basis for effective combination cancer chemotherapy with antimetabolites.

  2000cites this paper
• Maintenance of differential methotrexate toxicity between cells expressing drug-resistant and wild-type dihydrofolate reductase activities in the presence of nucleosides through nucleoside transport inhibition.

  2000cites this paper
• Where do we stand with 5-fluorouracil?

  1999cites this paper
• Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced α1-acid glycoprotein binding

  1999cites this paper
• Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.

  1997cites this paper
• Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage.

  1997cites this paper
• Pharmacokinetic Optimisation of Cancer Chemotherapy

  1997cites this paper
• Multifunctional modulators of drug resistance.

  1996cites this paper
• Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase

  1996cites this paper
• Dipyridamole mediated enhanced antiproliferative activity of 10‐ethyl‐10‐deazaaminopterin (10‐EDAM) against human lung cancer cell lines

  1996cites this paper
• Nucleoside and nucleobase transport systems of mammalian cells.

  1996cites this paper
• [Studies on reversing effect of multidrug resistance by dipyridamole. I. modulation of epirubicin-induced effects on cell proliferation and cell cycle by dipyridamole].

  1996cites this paper
• p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer.

  1996cites this paper
• [Studies on reversing effect of multidrug resistance by dipyridamole. II. Inhibition of epirubicin efflux from resistant cells by dipyridamole and its pharmacological effect].

  1996cites this paper
• Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.

  1995cites this paper
• Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression.

  1995cites this paper
• Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis.

  1995cites this paper
• Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects

  1994cites this paper
• Antimetabolites: Historical Perspectives

  1994cites this paper
• In vitro splicing of pre-messenger RNA with extracts from 5-fluorouridine-treated cells.

  1994cites this paper
• The syndrome of 5‐fluorouracil cardiotoxicity. An elusive cardiopathy

  1993cites this paper
• Clinical pharmacokinetics of anti-metabolites.

  1993cites this paper
• Current advances in the treatment of gastrointestinal malignancy.

  1993cites this paper
• Partitioning and thermodynamics of dipyridamole in the n‐octanol/buffer and liposome systems

  1993cites this paper
• Current advances in the treatment of gastrointestinal malignancy

  1993cites this paper
• 5-Fluorouracil modulation in colorectal carcinoma experience of German investigators.

  1993cites this paper
• A comparison of the abilities of nitrobenzylthioinosine, dilazep, and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin).

  1992cites this paper
• Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro.

  1992cites this paper
• 5-Fluorouracil's cytotoxicity is enhanced both in vitro and in vivo by concomitant treatment with hyperthermia and dipyridamole

  1992cites this paper
• Biochemical modulation of fluorouracil by dipyridamole: preclinical and clinical experience.

  1992cites this paper
• The emerging role for biomodulation of antineoplastic agents.

  1992cites this paper
• [Sequential methotrexate and 5-fluorouracil, doxorubicin, and cisplatin for advanced urothelial cancer].

  1992cites this paper
• Dipyridamole augments the antitumor effects of fluorinated pyrimidines.

  1992cites this paper
• Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.

  1991cites this paper
• Regulation of de novo and salvage pathways in chemotherapy.

  1991cites this paper
• Clinical relevance of biochemical modulation of 5-fluorouracil.

  1991cites this paper
• Potentiation of pirarubicin cytotoxicity by dipyridamole in doxorubicin-resistant mouse P388 leukemia cells.

  1991cites this paper
• Modulation of the activity of cancer chemotherapeutic agents by dipyridamole.

  1991cites this paper
• Dipyridamole binding to proteins in human plasma and tissue culture media.

  1991cites this paper
• Effect of nucleoside transport inhibitors on thymidine salvage and the toxicity of nucleoside analogs in mouse bone marrow granulocyte-macrophage progenitor cells.

  1991cites this paper
• Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators.

  1991cites this paper
• Potentiation by dipyridamole of 5-fluorouridine antitumor activity against a rat adenocarcinoma in vivo.

  1990cites this paper
• Modulation of cytotoxic drug activity by dipyridamole.

  1990cites this paper
• Metabolism and mechanism of action of 5-fluorouracil.

  1990cites this paper
• Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion.

  1990cites this paper
• Synergistic Drug Combinations in AIDS Therapy

  1990cites this paper
• Effect of dipyridamole on transport and phosphorylation of thymidine and 3'-azido-3'-deoxythymidine in human monocyte/macrophages.

  1990cites this paper
• Azidothymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-fluorouracil in rat hepatoma and human colon cancer cells.

  1990cites this paper
• Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers.

  1990cites this paper